|
Q3 FY2026
As of Jun 30, 2026
|
Q2 FY2026
As of Mar 31, 2026
|
Q1 FY2026
As of Dec 31, 2025
|
Q4 FY2025
As of Sep 30, 2025
|
Q3 FY2025
As of Jun 30, 2025
|
Q2 FY2025
As of Mar 31, 2025
|
Q1 FY2025
As of Dec 31, 2024
|
Q4 FY2024
As of Sep 30, 2024
|
Q3 FY2024
As of Jun 30, 2024
|
Q2 FY2024
As of Mar 31, 2024
|
Q1 FY2024
As of Dec 31, 2023
|
Q4 FY2023
As of Sep 30, 2023
|
Q3 FY2023
As of Jun 30, 2023
|
Q2 FY2023
As of Mar 31, 2023
|
Q1 FY2023
As of Dec 31, 2022
|
Q4 FY2022
As of Sep 30, 2022
|
Q3 FY2022
As of Jun 30, 2022
|
Q2 FY2022
As of Mar 31, 2022
|
Q1 FY2022
As of Dec 31, 2021
|
Q4 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Cash | ||||||||||||||||||||
| Cash and due from banks | ||||||||||||||||||||
| Interest earning deposits with banks | ||||||||||||||||||||
| Total cash and cash equivalents | ||||||||||||||||||||
| Investment securities - available for sale, at fair value | ||||||||||||||||||||
| Investment securities - held to maturity, at amortized cost (fair value of $60,924 and $61,160 at June 30, 2026 and September 30, 2025, respectively) | ||||||||||||||||||||
| Federal Home Loan Bank of New York stock, at cost | ||||||||||||||||||||
| Loans receivable, net of allowance for loan losses of $8,378 and $8,433 at June 30, 2023 and September 30, 2022, respectively | ||||||||||||||||||||
| Loans receivable | ||||||||||||||||||||
| Allowance for credit losses-loans | ||||||||||||||||||||
| Bank owned life insurance | ||||||||||||||||||||
| Accrued interest receivable | ||||||||||||||||||||
| Premises and equipment, net | ||||||||||||||||||||
| Other real estate owned ("OREO") | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities | ||||||||||||||||||||
| Deposits | ||||||||||||||||||||
| Escrowed funds | ||||||||||||||||||||
| Borrowings | ||||||||||||||||||||
| Accrued interest payable | ||||||||||||||||||||
| Accounts payable and other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders' equity | ||||||||||||||||||||
| Common stock: $.01 Par Value, 14,000,000 shares authorized; 7,097,825 shares issued; 6,457,203 and 6,480,028 shares outstanding at June 30, 2026 and September 30, 2025, respectively, at cost | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Treasury stock: 640,622 and 617,797 shares at June 30, 2026 and September 30, 2025, respectively, at cost | ||||||||||||||||||||
| Unearned Employee Stock Ownership Plan shares | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total stockholders' equity | ||||||||||||||||||||
| Total liabilities and stockholders' equity | ||||||||||||||||||||
Loading...
